Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 20Neoplasms 19Stomach Neoplasms 15Colorectal Neoplasms 15Lung Neoplasms 13Endometrial Neoplasms 13Pancreatic Neoplasms 11Leukemia, Myeloid, Acute 10Colonic Neoplasms 9Carcinoma, Hepatocellular 9Oropharyngeal Neoplasms 6Neoplasm Metastasis 6Multiple Myeloma 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Esophageal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Rectal Neoplasms 5Mouth Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Head and Neck Neoplasms 5Uterine Cervical Neoplasms 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Observation × Clear all
NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmSarcomaThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT02700724 2018-08-13

Observation Versus Immediate Surgery of Low Risk Bladder Cancer

Vanderbilt University Medical Center

Phase NA Terminated
8 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡